Requirements before biologically derived vaccine administered to patients


Published on

The U.S. Food and Drug Administration (FDA), released a report that advocated the Quality-by-design approach of process validation for the pharmaceutical industry. Learn what the new approach means and its potential impact.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Requirements before biologically derived vaccine administered to patients

  1. 1.  „PharmaceuticalQuality for the 21st Century: A Risk-Based Approach‟ is a FDA report  Quality-by-design approach of process validation for the pharmaceutical industry New approach includes  Process Development, Process Analytical Technologies, and Corrective and Preventive Actions (CAPA)
  2. 2.  TheFDA takes a “fragmented” approach to process development  According to compliance specialist Michael R. Goodman from Compliance Insight Goodman: pharmaceutical companies need to prioritize process development Enhance risk-mitigation through intentional and careful review of problems that could develop from internal and external factors
  3. 3.  Necessary steps include  Process development  Equipment audit  Targeted research to create supporting documentation for process validation  Quality-by-design – validation  Process analytical technologies (PAT)  Preventative and Corrective Actions
  4. 4.  Thefollowing can be achieved with this approach  Mitigating potential risk, maximizing understanding of the process, and establishing in-process controls Purpose: provide scientific and supporting evidence of a controlled process Provide in-depth characterization studies in case of out-of-specification investigation, according to Goodman
  5. 5.  Take the issue of determining what the factors are for administrating biologically derived pharmaceuticals to better understand the concept Examples  validated analytical methods;  qualified instruments;  maintenance and calibration programs; change control program;  identification of critical process and parameter markers, with their respective acceptance range;  bio-assays defined and qualified;  defined raw materials;  defined equipment, utilities, and services;  defined process parameters and acceptance range;  standard operating procedures; process documentation;  critical analysis/risk-analysis;  validation master plan; checks and controls for equipment, services, and utilities.
  6. 6.  The important factors include  Observing Quality by Design (QbD)  Risk Based Method  Process to undergo Design of Experiments (DOE)  Operational Limits  Purpose of Step  Defining variability range  Perform at lab scale  Potential investigative evidence
  7. 7.  Thecomplete deployment of Quality-by- design must include  Every aspect of the ingredients and material including right up to what packaging would be used  Equipment monitoring, maintenance and calibration  Emphasis on the process design and implementation of the most efficient manufacturing process  Critical measures and procedures to ensure and maintain quality at every step
  8. 8.  Momentum behind Quality-by-design is a result of the fact that it can produce better pharmaceuticals Requires manufacturers to increase their involvement in drug development and production monitoring Adds cost
  9. 9.  Compliance Insight, Inc. Your Hands-On Quality and Regulatory Specialists Our services include GMP consulting, audit preparation, FDA mock inspections, FDA response assistance, vendor/contract audits, GMP training and accreditation, new construction compliance, regulatory consulting, investigations, biosafety and viral testing consulting; clinical trial audits and more. For more information visit http://compliance-